Continuous Glucose Monitoring (CGM)
Treatment for Diabetes Mellitus Type 1
Typical Dosage: Continuous wear of sensor
Effectiveness
85%
Safety Score
90%
Clinical Trials
417
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
90
DangerousModerateSafe
Treatment Details
Dosage Range
Continuous wear of sensor
Time to Effect
Immediate (data display), weeks-months for improved control
Treatment Duration
Lifetime (continuous use)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$3,500
Side Effect Mgmt:$50
Total Annual:$3,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$4,176
Comparison vs Self-Monitoring of Blood Glucose (SMBG)
Cost Difference
+$2,550/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$1,760
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$50/year
Travel + wait time
Insurance Admin Cost
$60/year
Prior auth, claims
Rx Price
$3,500/year
Potential OTC Price
$2,000/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
Continuous Glucose Monitoring (CGM) Outcomes
for Diabetes Mellitus Type 1
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Common Side Effects
Skin irritation at sensor site
+10%
Sensor malfunction
+2%
Active Clinical Trials
4 active trials recruiting for Continuous Glucose Monitoring (CGM) in Diabetes Mellitus Type 1
Safety and Performance Evaluation of the SAVA Continuous Glucose Monitor for Effective Glucose Detection
NCT07679347NOT YET RECRUITINGNA
20 participants
INTERVENTIONAL
Started: Aug 1, 2026
Argus 2.0 Adoption Study
NCT07425236NOT YET RECRUITINGNA
100 participants
INTERVENTIONAL
San Mateo, United States
Started: Apr 19, 2026
PMCF Study of GX-01S CGM in Adults With Diabetes
NCT07802327NOT YET RECRUITINGNA
100 participants
INTERVENTIONAL
Started: Sep 1, 2026
Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System
NCT07745244RECRUITINGNA
36 participants
INTERVENTIONAL
Zibo, China
Started: Jun 1, 2026
Completed Clinical Trials
12 completed trials for Continuous Glucose Monitoring (CGM) in Diabetes Mellitus Type 1
Continue Glucose Monitoring Before Insulin Pump
NCT02813421COMPLETEDNA
11 participants
INTERVENTIONAL
Los Angeles, United States
Started: Mar 1, 2016
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
NCT03263494COMPLETEDPHASE3
153 participants
INTERVENTIONAL
Los Angeles, United States +13 more
Started: Jan 25, 2018
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
NCT04436822COMPLETEDNA
317 participants
INTERVENTIONAL
Escondido, United States +17 more
Started: Jul 15, 2020
Continuous Glucose Monitor in Children With Poorly Controlled Diabetes
NCT02530450COMPLETED
30 participants
OBSERVATIONAL
Started: May 1, 2011
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
NCT05908448COMPLETED
134 participants
OBSERVATIONAL
Atlanta, United States
Started: Feb 7, 2024
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
NCT03808376COMPLETEDNA
208 participants
INTERVENTIONAL
Concord, United States +7 more
Started: Dec 27, 2018
Strategies to Enhance New CGM Use in Early Childhood (SENCE)
NCT02912728COMPLETEDNA
143 participants
INTERVENTIONAL
Indianapolis, United States
Started: Jan 30, 2017
Predictive A1c Based on CGM Data Using CGM Data
NCT03898076COMPLETED
60 participants
OBSERVATIONAL
Doha, Qatar
Started: Jun 1, 2020
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
NCT02258373COMPLETEDNA
226 participants
INTERVENTIONAL
Beverly Hills, United States +13 more
Started: Mar 1, 2015
Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
NCT01586065COMPLETEDNA
10 participants
INTERVENTIONAL
Jacksonville, United States
Started: Feb 1, 2012
CGM Precision and Glycaemic Variability
NCT03842683COMPLETED
472 participants
OBSERVATIONAL
Started: Jun 6, 2016
Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).
NCT04094064COMPLETEDNA
20 participants
INTERVENTIONAL
Charlottesville, United States
Started: Feb 19, 2020
Showing 20 of 461 total trials